<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136451">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324999</url>
  </required_header>
  <id_info>
    <org_study_id>09-2326</org_study_id>
    <nct_id>NCT01324999</nct_id>
  </id_info>
  <brief_title>Tadalafil for Sarcoidosis Associated Pulmonary Hypertension</brief_title>
  <acronym>SAPH</acronym>
  <official_title>Tadalafil for Sarcoidosis Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy and safety of tadalafil in patients with
      Sarcoidosis Associated Pulmonary Hypertension.

      Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients
      with Sarcoidosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6 minute walk distance</measure>
    <time_frame>5 months of therapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Sarcoidosis Associated Pulmonary Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarcoidosis Associated Pulmonary Hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>20mg/day for one month then 40mg/day for additional 4 months</description>
    <arm_group_label>Sarcoidosis Associated Pulmonary Hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven sarcoidosis

          -  Mean pulmonary artery pressure &gt; 25 mmHg at rest or greater than 30 mmHg with
             exercise by right heart catheterization within 1 year prior to entry into study

          -  Pulmonary capillary wedge pressure ≤ 15 mmHg

          -  PVR values ≥ 3.0 Woods units

          -  Forced vital capacity (FVC) &gt; 40% predicted

          -  Forced expiratory volume in 1 second (FEV1) &gt; 40% predicted

          -  WHO functional class II or III

          -  Stable sarcoidosis treatment regimen for three months prior to entry into study

          -  6 minute walk distance between 150-450 meters

          -  Stable dose of antihypertensive medications

          -  On no other medication to treat PAH (sildenafil, vardenafil, treprostinil,
             epoprostenol, iloprost, bosentan, ambrisentan) within one month prior to enrollment
             and during duration of the study

          -  Non-pregnant females

        Exclusion Criteria:

          -  Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)

          -  Severe systemic hypertension &gt; 170/95

          -  Severe systemic hypotension &lt; 90/50

          -  History of priapism

          -  Patients with congestive heart failure (left ventricular dysfunction) LVEF &lt; 45% by
             echocardiogram

          -  Anticipation by the investigator for escalation in sarcoidosis treatment during the
             course of the study

          -  Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV,
             scleroderma, chronic thromboemboli)

          -  Use within 1 month of an sildenafil or vardenafil

          -  WHO functional class IV status

          -  Patients with severe other organ disease felt by investigators to impact on survival
             during the course of the study

          -  Subjects with liver function abnormalities (ALT or AST &gt; 3 times the upper limit of
             normal at screening or at baseline) or chronic liver disease

          -  Advanced kidney failure (GFR &lt; 30 ml/min at screening or at baseline)

          -  History of hypersensitivity reaction or adverse effect related to tadalafil

          -  Pregnant or lactating women

          -  Concomitant use of nitrates (any form) either regularly or intermittently

          -  Concomitant use of potent CYP3A inhibitors (eg, ritonavir, ketoconazole,
             itraconazole)

          -  Any additional contraindications and precautions specified in the package inserts for
             Tadalafil (Adcirca) not listed above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert J Ford, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>H. James Ford, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcoidosis Associated Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
